penpulimab-kcqx

Indications

• in combination with either cisplatin or carboplatin & gemcitabine for first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma
• as a single agent for the treatment of adults with metastatic non-keratinizing nasopharyngeal carcinoma with disease progression on or after platinum-based chemotherapy & at least one other prior line of therapy

Contraindications

• Embryo-Fetal Toxicity

Dosage

• 200 mg IV over 60 minutes every 2-3* weeks until disease progression or a maximum of 24 months

* every 2 weeks as single agent

* every 3 weeks with either cisplatin or carboplatin & gemcitabine

Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.

Adverse effects

• serious or fatal immune-mediated reactions can occur in any organ of the body
• most common (> 20%)
  • in combination with either cisplatin or carboplatin & gemcitabine:
    • nausea, vomiting, hypothyroidism, constipation, decreased appetite, weight loss, cough, COVID-19 infection, fatigue, rash, pyrexia
  • as single agent (> 20%)
    • anemia, hypothyroidism

• drug adverse effects of checkpoint inhibitor(s)
• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• programmed death receptor-1 blocking antibody (PD-1 inhibitor)

More general terms

• antineoplastic monoclonal antibody
• checkpoint inhibitor